#atrial-fibrillation #catheter-ablation #ablation-technology #ventricular-arrhythmias

Pulsed-Field Ablation (PFA)

Definition

Pulsed-field ablation (PFA) is a non-thermal catheter-based energy modality that uses high-voltage electrical pulses to achieve irreversible electroporation of cardiac cell membranes. Unlike radiofrequency or cryoablation, PFA is tissue-selective — cardiac myocytes are preferentially susceptible — and does not cause coagulative necrosis, conferring specific safety advantages for adjacent non-cardiac structures (oesophagus, phrenic nerve, pulmonary vein walls).

Key Concepts

Mechanism and Core Advantages

Tissue selectivity: Cardiac myocytes are selectively susceptible to electroporation fields; adjacent oesophagus, phrenic nerve, and PV walls are spared (sources/ca-af-ehj-2024, rating: high)
No coagulative necrosis: Eliminates risk of PV stenosis — a recognized complication of RF ablation (sources/ca-af-ehj-2024)
Ultra-rapid application: Significantly shorter procedure time compared with RF point-by-point ablation (sources/ca-af-ehj-2024)
Not contact-force dependent: Does not require the CF monitoring needed for RF ablation (sources/ca-af-ehj-2024)

Clinical Evidence

ADVENT trial (PAF) — first RCT: PFA non-inferior to conventional thermal ablation (RF or cryoballoon) for the composite primary efficacy endpoint (freedom from treatment failure: 73.3% PFA vs 71.3% thermal; between-group difference 2.0 pp; 95% BCI −5.2 to 9.2; posterior probability of NI >0.999) at 1 year; 607 patients; 30 US centers; Bayesian noninferiority design (sources/pfa-advent-nejm-2023, rating: very high)
ADVENT primary safety: Serious adverse events 2.1% PFA vs 1.5% thermal (posterior probability of NI >0.999); one procedure-related death (catheter manipulation, not PFA energy); persistent phrenic nerve paralysis in 2 cryoballoon patients, 0 in PFA (sources/pfa-advent-nejm-2023, rating: very high)
ADVENT PV stenosis — PFA superior: Mean PV cross-sectional area change −0.9% (PFA) vs −12.0% thermal (posterior probability of superiority >0.999); RF subgroup −19.5%; cryo subgroup −3.3%; no clinical PV stenosis in either arm (sources/pfa-advent-nejm-2023, rating: very high)
ADVENT procedure time: PFA shorter total procedure time (105.8 vs 123.1 min) but greater fluoroscopy use (21.1 vs 13.9 min); PVI success comparably high (99.6% vs 99.8%) (sources/pfa-advent-nejm-2023, rating: very high)
ADVENT cerebral lesion signal: 3/33 (9.1%) PFA patients had asymptomatic MRI-detected cerebral lesions within 48h vs 0/37 thermal — small substudy, underpowered; single clinical stroke occurred in RF arm (sources/pfa-advent-nejm-2023, rating: very high)
SINGLE SHOT CHAMPION (PAF) — first RCT with superiority signal: PFA (Farapulse pentaspline) vs cryoabloon (Arctic Front) in 210 patients with symptomatic paroxysmal AF; all patients received implantable cardiac monitor for continuous rhythm monitoring; PFA met noninferiority AND formal superiority (37.1% vs 50.7% recurrence days 91–365; difference −13.6 pp; 95% CI −26.9 to −0.3; P<0.001 NI, P=0.046 superiority); per-protocol: 37.1% vs 51.7% (−14.6 pp; P<0.001 NI); adjusted HR 0.66 (95% CI 0.43–1.01) (sources/pfa-cryo-singleshotchampion-nejm-2025, rating: high)
SINGLE SHOT CHAMPION procedure time: PFA 55 min vs cryo 73 min (difference −18.3 min; 95% CI −25.1 to −11.6); fluoroscopy similar (14.6 vs 15.1 min) (sources/pfa-cryo-singleshotchampion-nejm-2025, rating: high)
SINGLE SHOT CHAMPION troponin: High-sensitivity troponin day 1: 1920±954 ng/L (PFA) vs 1114±419 ng/L (cryo); +823 ng/L with PFA — supports hypothesis of broader ablation zone with PFA ("PV ablation" vs "PV isolation") (sources/pfa-cryo-singleshotchampion-nejm-2025, rating: high)
SINGLE SHOT CHAMPION blanking period: Recurrence also lower with PFA during blanking period (days 1–90): −20.0 pp (95% CI −33.2 to −6.8); arrhythmia burden days 1–90: −2.4 pp (95% CI −4.5 to −0.3); suggests less procedural inflammation with PFA — consistent with rare pericarditis post-PFA; challenges traditional use of 90-day blanking period (sources/pfa-cryo-singleshotchampion-nejm-2025, rating: high)
SINGLE SHOT CHAMPION safety: Safety composite (tamponade, phrenic nerve palsy, vascular complications, stroke/TIA, atrioesophageal fistula, death within 30 days): 1/105 PFA (1 stroke) vs 2/105 cryo (2 tamponades); no atrioesophageal fistula, no PV stenosis, no phrenic nerve palsy in either group (sources/pfa-cryo-singleshotchampion-nejm-2025, rating: high)
SINGLE SHOT CHAMPION repeat ablation: Numerically more repeat procedures in PFA arm (16 vs 10; rate ratio 1.60; 95% CI 0.76–3.37) — not statistically significant but worth monitoring in longer follow-up (sources/pfa-cryo-singleshotchampion-nejm-2025, rating: high)
PULSED AF and PersAFOne: Confirmed safety and efficacy in both PAF and persistent AF; adjunctive LAPW ablation demonstrated feasible (sources/ca-af-ehj-2024)
European real-world all-comer registry: Safe and effective for PVI and additional extra-PV lesions (mostly LAPW) in an unselected AF population (sources/ca-af-ehj-2024)
AVANT GUARD (Persistent AF, first-line) — first persistent AF RCT: International multicenter RCT (n=310 randomized; 2:1 PFA vs AAD) in previously untreated persistent AF; PFA (PVI + posterior wall ablation with pentaspline FARAWAVE catheter) vs antiarrhythmic drug therapy; all patients received insertable cardiac monitor (LUX-Dx) for continuous rhythm monitoring; treatment success at 12 months: 56% PFA vs 30% AAD (HR for treatment failure 0.46; 95% CI 0.33–0.65; P<0.001); between-group difference 26 pp (95% CI 14–38) (sources/PFA-LPeAF-AVANT-GUARD-NEJM-2026, rating: very high)
AVANT GUARD burden: Median AF burden at 12 months: 0% (PFA) vs 0.2% (AAD); mean difference −6.5 pp; asymptomatic AT/AF ≥1h: 30% PFA vs 46% AAD; symptomatic AT/AF ≥30s: 2% vs 3% (sources/PFA-LPeAF-AVANT-GUARD-NEJM-2026, rating: very high)
AVANT GUARD safety signal — stroke: Primary safety endpoint met (5.1% SAEs vs 12% performance goal) but 6 procedure-related strokes (2%) observed, including 1 air embolization from deflectable sheath; all NIHSS <5 with clinical improvement/full recovery; trial temporarily paused → protocol modifications (mandatory TEE/CT <24h for LA thrombus, uninterrupted OAC ≥4 weeks, ACT ≥350s, exclude CHA₂DS₂-VASc ≥4) → 0 strokes after pause; safety pre-pause 6% vs post-pause 3% (sources/PFA-LPeAF-AVANT-GUARD-NEJM-2026, rating: very high)
AVANT GUARD procedural: Mean procedure time 85±32 min; LA dwell time 51±20 min; 45±11 applications for PVI + 25±9 for posterior wall ablation; CTI ablation in 8.2% (sources/PFA-LPeAF-AVANT-GUARD-NEJM-2026, rating: very high)
AVANT GUARD population: Older and sicker than prior first-line AF ablation trials (mean age 68, CHA₂DS₂-VASc 2.6, HTN 65%, DM 23%, sleep apnea 24%); 80% first persistent AF diagnosis <1 year; generalizable to real-world clinical practice (sources/PFA-LPeAF-AVANT-GUARD-NEJM-2026, rating: very high)
MANIFEST-PF retrospective registry: Adjunctive LAPWI with PFA not beneficial at 12 months; criticised for small sample (131 patients/24 centres), unverified lesion durability, variable operator protocol, and inconsistent arrhythmia monitoring (sources/ca-af-ehj-2024)

Safety Profile

No PV stenosis: Absence of coagulative necrosis eliminates this classic RF complication (sources/ca-af-ehj-2024)
No oesophageal injury or phrenic nerve palsy: Core advantage; documented across multiple studies (sources/ca-af-ehj-2024)
Coronary vasospasm: Risk when energy is delivered adjacent to coronary artery; effectively attenuated by prophylactic nitroglycerin administration (sources/ca-af-ehj-2024)
Acute kidney injury (AKI): Secondary to intravascular haemolysis; dose-dependent on number of PFA applications; preventable by planned peri-procedural fluid infusion (sources/ca-af-ehj-2024)
Pulmonary hypertension: PFA prevents worsening of pulmonary hypertension (unlike RF) in AF patients with baseline stiff left atrial syndrome (sources/ca-af-ehj-2024)
Thromboembolic events: TIA 0.8% (IMPULSE/PEFCAT I/II); stroke 0.39%, TIA 0.11% (MANIFEST-PF); AVANT GUARD: 2% stroke rate (6/257) with pentaspline catheter in older persistent AF population, reduced to 0% after protocol modifications (mandatory TEE/CT, uninterrupted OAC ≥4 weeks, ACT ≥350s, CHA₂DS₂-VASc exclusion ≥4) (sources/ca-af-ehj-2024, sources/PFA-LPeAF-AVANT-GUARD-NEJM-2026)

Gaps and Future Directions

Longer-term safety data are still absent (sources/ca-af-ehj-2024)
Optimal role of adjunctive ablation beyond PVI in persistent AF with PFA requires dedicated RCTs (sources/ca-af-ehj-2024)
Applicability in all-comer AF populations and full characterisation of rare side effects (AKI, coronary vasospasm) require large-scale trials (sources/ca-af-ehj-2024)

Ventricular PFA (Emerging)

PFA has been used for ventricular arrhythmias (PVCs and VT) but experience remains limited; no large published series (sources/PVC-ablation-jaccep-2024, rating: high)
Tissue selectivity (cardiomyocyte-specific) and minimal heat generation are theoretically advantageous for ventricular use: reduced risk of steam pops, char formation, and thromboembolism compared with RF (sources/PVC-ablation-jaccep-2024)
No specific ventricular PFA outcome data available at time of 2024 review; characterised as "emerging" (sources/PVC-ablation-jaccep-2024)

Contradictions / Open Questions

MANIFEST-PF found no benefit of adjunctive LAPWI with PFA at 12 months, in contrast to RF/cryo-based meta-analyses showing benefit; methodological limitations of MANIFEST-PF make the negative result uncertain (sources/ca-af-ehj-2024)
Optimal lesion set beyond PVI in persistent AF with PFA is unresolved; no dedicated RCT yet completed (sources/ca-af-ehj-2024)
Long-term durability of PFA lesions (vs RF or cryo) not yet established; ADVENT and SINGLE SHOT CHAMPION both limited to 1-year follow-up (sources/pfa-advent-nejm-2023, sources/pfa-cryo-singleshotchampion-nejm-2025)
Asymptomatic cerebral lesions signal: 3/33 (9.1%) PFA vs 0/37 thermal in the ADVENT MRI substudy; underpowered to draw conclusions; mechanism unclear (thromboembolic vs air/debris); requires dedicated prospective evaluation (sources/pfa-advent-nejm-2023)
Both ADVENT and SINGLE SHOT CHAMPION results apply to the pentaspline catheter (Farapulse) only; not generalizable to other PFA platforms (sources/pfa-advent-nejm-2023, sources/pfa-cryo-singleshotchampion-nejm-2025)
PFA superiority signal (SINGLE SHOT CHAMPION) vs noninferiority only (ADVENT): SINGLE SHOT CHAMPION showed P=0.046 for superiority — borderline; driven partly by continuous ICM monitoring and operator experience; needs replication in a larger confirmatory RCT (sources/pfa-cryo-singleshotchampion-nejm-2025, sources/pfa-advent-nejm-2023)
Blanking period necessity for PFA: Lower early recurrence in SINGLE SHOT CHAMPION PFA arm suggests reduced procedural inflammation with PFA; whether the 90-day blanking period is needed for PFA specifically requires prospective evaluation (sources/pfa-cryo-singleshotchampion-nejm-2025)
Repeat ablation numerically higher with PFA: SINGLE SHOT CHAMPION: 16 vs 10 repeat ablations (PFA vs cryo; rate ratio 1.60; NS) — could reflect higher recurrence detection rate with ICM in PFA patients who had more aggressive re-intervention, or a real PVI durability signal; requires longer follow-up (sources/pfa-cryo-singleshotchampion-nejm-2025)
PFA stroke risk in older persistent AF populations: AVANT GUARD found a 2% stroke rate (6/257) in an older (mean age 68), sicker persistent AF population — higher than prior PFA studies (ADVENT: 0.6% stroke in thermal arm; MANIFEST-17K: 0.1%). Protocol modifications eliminated further strokes, but the relative contribution of patient factors vs procedural factors is unclear (only 29% of patients treated after the pause). The 5.1% overall SAE rate was below the 12% performance goal, indicating acceptable overall safety, but stroke risk mitigation protocols (TEE/CT, uninterrupted OAC, ACT ≥350s, CHA₂DS₂-VASc exclusion) should be considered for higher-risk persistent AF patients (sources/PFA-LPeAF-AVANT-GUARD-NEJM-2026)
Posterior wall ablation with PFA: AVANT GUARD performed PVI + posterior wall ablation universally, differing from the PVI-only approach of ADVENT. Whether posterior wall ablation adds efficacy or risk with PFA specifically is unresolved — CAPLA (RF: no LAPWI benefit) may not apply to PFA (sources/PFA-LPeAF-AVANT-GUARD-NEJM-2026)
Long-term outcomes: Both SINGLE SHOT CHAMPION and AVANT GUARD are limited to 1-year follow-up; long-term durability of PFA lesions in both paroxysmal and persistent AF populations unknown (sources/PFA-LPeAF-AVANT-GUARD-NEJM-2026, sources/pfa-cryo-singleshotchampion-nejm-2025)

Connections

Related to concepts/Catheter-Ablation-AF
Related to entities/Atrial-Fibrillation
Related to sources/ca-af-ehj-2024